Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus

Journal of Rheumatology

Volumn 26, Issue 2, 1999, Pages 432-439

  Baca, Vicente ^a   Lavalle, Carlos ^a   García, Rubén ^a   Catalán, Teresa ^a   Sauceda, Juan M ^a   Sánchez, Gerardo ^a   Martínez, Irma ^a   Ramírez, Martha L ^a   Márquez, Luis M ^a   Rojas, Juan C ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

Author keywords

Central nervous system; Pulse cyclophosphamide; Pulse methylprednisolone; Systemic lupus erythematosus

Indexed keywords

ACICLOVIR; ANTICONVULSIVE AGENT; CHLOROQUINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; NEUROLEPTIC AGENT; PREDNISONE;

ADOLESCENT; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MENTAL DISEASE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS; BRAIN DISEASES; CHILD; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; METHYLPREDNISOLONE; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0032956554     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994;20:129-58.
2. Kovacs JAJ, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1993; 19:795-813.
3. Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981;24:1389-95.
4. Cassidy JT, Sullivan DB, Petty RE, Ragsdale C. Lupus nephritis and encephalopathy. Prognosis in 58 children. Arthritis Rheum 1977;20:315-22.
5. Steinlin MI, Blaser SI, Gilday DL, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995;13:191-7.
6. Parikh S, Swaiman KF, Kim Y. Neurologic characteristics of childhood lupus erythematosus. Pediatr Neurol 1995;13:198-201.
7. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
8. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus: Q J Med 1991;81:975-84.
9. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus - the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 1992;19:370-2.
10. Neuwelt CM, Lacks S, Kaye BR, Ellman JB. Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington: American Psychiatric Association; 1987.
13. Baca V, Sanchez VG, Martinez MI, Ramirez LM, Lavalle C. Successful treatment of transverse myelitis in a child with systemic lupus erythematosus. Neuropediatrics 1996;27:42-4.
14. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869-74.
15. McCune WJ, MacGuire A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988;31:159-66.
16. Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995;21:81-98.
17. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971;50:85-95.
18. Lee P, Urowitz MB, Bookman AA, et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977;46:1-32.
19. Abel T, Gladman DD, Urowitz MB. Neuropsychiatric lupus. J Rheumatol 1980;7:325-33.
20. Feng PH, Cheah PS, Lee YK. Mortality in systemic lupus erythematosus. A 10-year review. BMJ 1973;4:772-4.
21. Gibson T, Myers AR. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1976;35:398-406.
22. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 1976;55:323-9.
23. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus: a clinical-pathological study of 24 cases and review of the literature. Medicine 1968;47:337-69.
24. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992;19:47-52.
25. Sergent JS, Lockshin MD, Klempner MS, Lipsky BA. Central nervous system disease in systemic lupus erythematosus: therapy and prognosis. Am J Med 1975;58:644-54.
26. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 3rd ed. Philadelphia: WB Saunders; 1995.
27. Hughes GRV. Central nervous system lupus - diagnosis and treatment. J Rheumatol 1980;7:405-11.
28. Klippel JH. Is aggressive therapy effective for lupus? Rheum Dis Clin North Am 1993;19:249-61.
29. Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996;125:549-57.
30. Shaikow AV, Maximov AA, Speransky AI, Lovell DJ, Giannini EH, Solovyev SK. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a long-term study. J Rheumatol 1992; 19:612-6.
31. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1852-5.
32. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984;76:377-84.
33. Gelfand MC, Steinberg AD, Nagle R, Knepshield JH. Therapeutic studies in NZB/W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum 1972;15:239-46.
34. Steinberg AD, Gelfand MC, Hardin JA, Lowenthal DT. Therapeutic studies in NZB/W mice. III: Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum 1975;18:9-14.
35. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions. Arthritis Rheum 1998;41:761-7.
36. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:265-95.
37. Lavalle C, Pisarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990;17:34-7.
38. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.